R&D

Polio Set To get The Nanopatch Treatment from Vaxxas

Polio Set To get The Nanopatch Treatment from Vaxxas

Written by on September 22, 2014 in R&D with 0 Comments

Vaxxas announces a WHO funded project to evaluate the delivery of polio vaccine using Nanopatch Australian company Vaxxas last week announced the initiation of a research project designed to evaluate the commercialisation prospects of Nanopatch, their microneedle platform for the delivery of polio vaccine. Vaxxas’ Nanopatch consists of a 1cm2 square of silicon with around 20,000 […]

Continue Reading

Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

Written by on September 15, 2014 in Prophylactic Vaccines, R&D, Therapeutic Vaccines, Vaccines Live with 0 Comments

With the 15th World Vaccine Congress on 13 – 15 October in Brussels is just next month I conducted an interview to one of our key speakers, Dr. Niranjan Y. Sardesai (COO, Inovio Pharmaceuticals, Inc.) to give you further insight into his new exciting clinical data and current challenges in developing cancer DNA vaccines.  Dr. […]

Continue Reading

Therapeutic

The Problem with Cancer Vaccines

The Problem with Cancer Vaccines

You can’t treat a heterogeneous disease with a homogeneous treatment. That was the takeawy message from Vaccinogen’s founder at the World Vaccines Congress Europe Vaccine Nation caught up with Michael Hanna, the founder of Vaccinogen and creator of autologous patient-specific tuumor cell vaccine OncoVAX, to discuss why ther have been so many highprofile cancer vaccine failures and […]

Continue Reading

Japan May Provide West African Countries With Unapproved Ebola Treatment

Japan May Provide West African Countries With Unapproved Ebola Treatment

Written by on August 27, 2014 in Featured on App, News, Therapeutic Vaccines with 0 Comments

The Japanese government is ready to provide Ebola afflicted countries an experimental drug that has not yet been approved by the WHO On Monday the 27th of August, Japan’s Chief Cabinet Secretary Yoshihide Suga announced that the country is willing to donate a flu drug called Favipiravir to aid the Ebola crisis in west Africa. […]

Continue Reading

Prophylactic

Johnson & Johnson To Fast Track Ebola Vaccine Trials

Johnson & Johnson To Fast Track Ebola Vaccine Trials

Written by on September 5, 2014 in Featured on App, News, Prophylactic Vaccines with 0 Comments

Amongst the flurry of efforts to combat the West African Ebola outbreak, Johnson & Johnson is trying its hand at developing a vaccine Johnson & Johnson can be counted amongst the ranks of yet another pharmaceutical company that has joined the race to develop an Ebola vaccine. Thus far, the most advanced vaccine candidate is Glaxo […]

Continue Reading

New Positive Dengue Vaccine Results From Sanofi’s Biggest Trial Yet

New Positive Dengue Vaccine Results From Sanofi’s Biggest Trial Yet

Written by on September 3, 2014 in Emerging Markets, Featured on App, Prophylactic Vaccines with 0 Comments

Sanofi today announced the positive results of a 20,000 strong phase III trial of their pioneering dengue vaccine This final study from Sanofi Pasteur, Sanofi’s vaccine arm, has demonstrated a 60.8 reduction in cases of dengue  fever amongst it’s 20,875 strong population of 9-16 year olds in Latin America. This was accompanied by a 80% […]

Continue Reading

Flu

Building a Universal Flu Vaccine

Building a Universal Flu Vaccine

Written by on October 23, 2014 in Featured on App, Features & Downloads, Flu with 0 Comments

Developing a universal flu vaccine requires a two part strategy targeted at the surface of the flu virus and it’s unchanging core At Last week’s World Vaccine Congress 2014, Vaccine Nation sat down with professor Sarah Gilbertson from the University of Oxford to discuss her progress towards developing a universal vaccine. What strategy are you […]

Continue Reading

Flu Vaccine Nasal Spray For Kids May Be More Cost Effective

Flu Vaccine Nasal Spray For Kids May Be More Cost Effective

Written by on September 2, 2014 in Featured on App, Flu, News with 0 Comments

As Flu season approaches, a study reveals that a nasal spray vaccine may be more cost effective to administer to children A study that has appeared in a recent issue of The American Journal of Pharmacy Benefits has analysed the cost-effectiveness of a nasal spray form of the flu vaccine versus the standard needle shot. […]

Continue Reading

Regulation & Policy

Vaccines and Autism: Infographic

Vaccines and Autism: Infographic

Written by on September 23, 2014 in Featured on App, Regulation and Policy with 0 Comments

Source: Healthcare-management-degree.net

Continue Reading

NIH Finds Unauthorised Toxic Samples In Safety Sweep

NIH Finds Unauthorised Toxic Samples In Safety Sweep

Written by on September 10, 2014 in Featured on App, News, Regulation and Policy with 0 Comments

Safety sweep of the NIH reveals presence of five dangerous toxic samples In July 2014, a number of unauthorised smallpox samples were discovered at the NIH’s headquarters in Bethseda, Maryland. This discovery spurred on a safety sweep of the NIH headquarters to verify the presence of any other unauthorised biological samples and toxins. On the […]

Continue Reading

Emerging Markets

The State of the Art of Electronic Health Records – Infographic

The State of the Art of Electronic Health Records – Infographic

Written by on August 22, 2014 in Emerging Markets, News with 0 Comments

In the next 10 years, data science and software will do more for medicine than all of the biological sciences together” Vinod Khosla, venture capitalist Last year, Vaccine Nation reported on research suggesting that the adoption of Electronic Health Records (EHR) could dramatically increase the ability of public health authorities to track immunizations amongst patient. […]

Continue Reading

Ebola Treatment Centre: An Interactive Guide

Ebola Treatment Centre: An Interactive Guide

Written by on August 19, 2014 in Emerging Markets, Featured on App, News with 0 Comments

The Golden Number: 42 Days With a while to wait before we see an approved Ebola vaccine become available, the virus must be effectively contained in order to see an end to the outbreak. The time it takes for symptoms to appear after exposure to the virus is known as the incubation period – and […]

Continue Reading

Supply Chain

The HPV Cancer Vaccine: Two Doses May Be Enough

The HPV Cancer Vaccine: Two Doses May Be Enough

Written by on August 28, 2014 in Featured on App, News, Prophylactic Vaccines, Supply Chain with 0 Comments

Studies have shown that two, instead of three doses, of the HPV vaccine may be enough to prevent the virus On Monday the 25th of August, the 29th International Papillomavirus Conference came to a close in Seattle, USA. Amongst the most hotly debated topics at the conference was lowering the number of doses of the […]

Continue Reading

Lost Small Pox Vials and Anthrax Mishaps

Lost Small Pox Vials and Anthrax Mishaps

Written by on July 15, 2014 in News, Regulation and Policy, Supply Chain with 0 Comments

  Will small pox and anthrax biosafety concerns undermine vital research? Last week the US Centres for Disease Control and Prevention announced that 6 small pox vials had been discovered on the 1st of July during the clearing out of an old laboratory at the Nationality Institute of Health’s (NIH) Bethesda campus, Maryland. The six […]

Continue Reading

Strategy and Partnering

Whistleblowers Reveal Merck Misrepresented Mumps Vaccine Efficacy

Whistleblowers Reveal Merck Misrepresented Mumps Vaccine Efficacy

Written by on September 10, 2014 in Featured on App, News, Partnering and Corporate strategy with 0 Comments

Two former Merck scientists have filed lawsuits against the company for misrepresenting efficacy results of its mumps vaccine Two former virologists for Merck have filed lawsuits against the company for misrepresenting efficacy results of its mumps vaccine. A US district judge from Pennsylvania, Darnell Jones II, has ruled that the pair of whistleblowers have provided […]

Continue Reading

Advaxis and Merck Partnership for Immunotherapy Prostate Cancer Drug Trial

Advaxis and Merck Partnership for Immunotherapy Prostate Cancer Drug Trial

Written by on September 4, 2014 in Featured on App, News, Partnering and Corporate strategy with 0 Comments

Advaxis and Merck have formed a partnership to conduct a clinical trial with their experimental prostate cancer drugs Advaxis and Merck have formed a partnership to test their experimental prostate cancer drugs, ADXS-PSA and anti PD-1 antibody pembrolizumab, to see if the combination of these two drugs will yield psoitive results in a phase I/II trial […]

Continue Reading

Other Recent Posts

ARTES Biotechnology, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development

ARTES Biotechnology, InstrAction and Q-Biologicals establish a three-party consortium for vaccine developments for veterinary applications. October 6, 2014 Under the title:” development of a virus-like-particle (VLP) based vaccine platform and stable formulation especially suited for the veterinary applications”, in short “Plurivax”, the EU cooperation is part of the recent 8th EuroTransBio call and will be funded for a three year […]

Continue Reading

ViroCyt and I&L Biosystems Launch Virus Counter® 3100 at the World Vaccine Congress in Brussels

October 2, 2014 ViroCyt, LLC, the leader in rapid virus quantification, announced today that, in partnership with I&L Biosystems GmbH, it is formally launching the Virus Counter® 3100 in Europe at the World Vaccine Congress to be held October 13-15 in Brussels, Belgium. “The Virus Counter 3100 is the marquee analytical tool for quickly quantifying […]

Continue Reading

New drug-delivery capsule may replace injections

Pill coated with tiny needles can deliver drugs directly into the lining of the digestive tract. October 1, 2014 Given a choice, most patients would prefer to take a drug orally instead of getting an injection. Unfortunately, many drugs, especially those made from large proteins, cannot be given as a pill because they get broken […]

Continue Reading

Top
Geolocation